Results 91 to 100 of about 1,034,736 (266)

Az apixaban hatékonysága és biztonságossága a warfarinhoz képest a terápiás tartományban töltött idő függvényében [Efficacy and safety of apixaban compared with warfarin regarding time within the therapeutic range] [PDF]

, 2014
Prevention of thromboembolism by lifelong anticoagulation is an important therapeutic goal in patients with atrial fibrillation according to recent guidelines.
Havasi Kálmán
core   +1 more source

The Mediating Effect of Intracranial Hemorrhage Status on the Relationship between the INR and Mortality in Patients with Ischemic Stroke

Neurology and Therapy
Introduction The international normalized ratio (INR) is a biomarker of coagulopathy. The objective of this study was to assess the relationship between the INR and clinical outcomes in patients with large vessel occlusion (LVO) stroke who received ...
Yapeng Guo, Lingshan Wu, Zhenxuan Tian, Xu Xu, Jinfu Ma, Changwei Guo, Linyu Li, Jie Yang, Wenjie Zi, Jiacheng Huang, Xianjun Huang   +10 more
doaj   +1 more source

THE INITIAL STAGE OF TESTING THE DEVELOPED APPARATUS TO DETERMINE THE INTERNATIONAL NORMALIZED RATIO

В мире научных открытий, 2018
Prothrombin time (PTT) is a laboratory indicator that allows to evaluate the external pathway of blood coagulation (activity of factors I, II, V, VII and X). An INR indicator was introduced to standardize the results of the PTV test. INR = (patient’s PTT/
Natalya Valeryevna Aksyutina, Vladimir Abramovich Shulman, Fedor Georgievich Zograf, Vasiliy Sergeyevich Mordovsky, Pavel Sergeevich Marinushkin, Mikhail Igorevich Gavrilenko, Viktor Vladimirovich Kusaev, Evgeny Nikolayevich Kononov, Sergey Sergeevich Petrov, Eduard Vasilyevich Semenov, Irina Sergeevna Knyazeva   +10 more
doaj   +1 more source

Telemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants.

European Heart Journal, 2015
AIM To study in patients performing international normalized ratio (INR) self-control the efficacy and safety of an INR target range of 1.6-2.1 for aortic valve replacement (AVR) and 2.0-2.5 for mitral valve replacement (MVR) or double valve replacement (
H. Koertke, A. Zittermann, O. Wagner, Songuel Secer, A. Sciangula, W. Saggau, F. Sack, J. Ennker, J. Cremer, F. Musumeci, J. Gummert   +10 more
semanticscholar   +1 more source

Does routine repeat testing of critical laboratory values improve their accuracy? [PDF]

, 2015
Background: Routine repeat testing of critical laboratory values is very common these days to increase their accuracy and to avoid reporting false or infeasible results. We figure that repeat testing of critical laboratory values has any benefits or not.
Kadivar, M., Motie, P.B., Shayanfar, N., Zare-Mirzaie, A.   +3 more
core   +1 more source

Exact buckling analysis of composite elastic columns including multiple delamination and transverse shear [PDF]

, 2008
The exact analytical solution of buckling in beams with multiple delaminations is presented. In order to investigate analytically the influence of axial and shear strains on buckling loads, the geometrically exact beam theory is employed with no ...
Planinc, Igor, Rodman, Urban, Saje, Miran, Zupan, Dejan   +3 more
core   +1 more source

Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.

American Journal of Kidney Diseases, 2015
BACKGROUND Anticoagulation management is difficult in chronic kidney disease, with frequent supratherapeutic international normalized ratios (INRs ≥ 4) increasing hemorrhagic risk.
N. Limdi, Thomas D. Nolin, Sarah L. Booth, A. Centi, Marisa B. Marques, Michael R. Crowley, M. Allon, T. Beasley   +7 more
semanticscholar   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Laboratory Reporting of the International Normalized Ratio: Progress and Problems

Archives of Pathology & Laboratory Medicine, 2007
Abstract Context.—The international normalized ratio (INR) is widely used to monitor oral anticoagulation and to evaluate patients with coagulation disorders. Objective.—To examine the variability of the performance and reporting of the INR and to evaluate laboratory calculation of the INR.
Mark T. Cunningham, Timothy E. Hayes, Robert S. Makar, Elizabeth M. Van Cott, Wayne L. Chandler, Kandice Kottke-Marchant, John T. Brandt, John D. Olson, Arby B. Uy, Edward Wang   +9 more
openaire   +3 more sources

Does warfarin prevent venous thromboembolic events in aPL-positive patients? [PDF]

, 2007
Yes, warfarin is effective in the secondary prevention of venous thromboembolic events (VTEs) for patients positive for lupus anticoagulant or anticardiolipin antibody (also known as antiphospholipid antibodies [aPL]) (strength of recommendation [SOR]: B,
Jamieson, Barbara, Mazzone, Michael F.
core